[ad_1] Victoria Klesty | Reuters In the U.S., Wegovy is no longer just for weight loss. The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage…
[ad_1] Close-up of a hand holding a cellphone displaying the Amazon Pharmacy system, Lafayette, California, September 15, 2021. Smith Collection | Gado | Getty Images Eli Lilly on Wednesday said Amazon Pharmacy will help send certain prescription drugs, including the red-hot weight loss treatment Zepbound, to patients’ homes through the drugmaker’s new direct-to-consumer program. Starting…
[ad_1] Nurphoto | Nurphoto | Getty Images Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched…
[ad_1] Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Cigna on Thursday said it will limit how much health plans and employers spend on weight loss drugs each year in a bid to expand insurance coverage for those highly…
[ad_1] This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim in eastern France. Sebastien Bozon | Afp | Getty Images Novo Nordisk‘s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial…
[ad_1] Cr | Istock | Getty Images Biotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Viking is just one of several companies racing to join the growing space. Some analysts say the market could be worth $100 billion by the…
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but…
[ad_1] Shares of Novavax fell more than 20% on Wednesday after the vaccine maker reported fourth-quarter revenue and earnings that missed Wall Street’s estimates and said it expects full-year 2024 sales to come in flat or lower than last year. Still, Novavax narrowed its losses in the quarter from the same period a year ago,…
[ad_1] Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 90% on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow…
[ad_1] Nikos Pekiaridis | Nurphoto | Getty Images Shares of Moderna closed roughly 13% higher Thursday after the company posted a surprise quarterly profit, boosted by deferred revenue and cost cuts, even as it saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and…
